Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Introduction There are numerous new systemic treatments for atopic dermatitis in various stages of development ... including studies on other forms of eczema/dermatitis such as chronic hand dermatitis ...
healthday on MSN8h
Breathing Dirty Air Might Raise Eczema RisksCases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research show ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
The odds of eczema are increased with greater exposure to fine particulate matter of diameter ≤2.5 μm, according to study findings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback